What happened with ALXO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ALX Oncology Holdings Inc. focuses on evorpacept and ALX2004, two cancer drug candidates in clinical development. The business depends heavily on evorpacept, with most development efforts and spending directed toward these two candidates. Neither has completed a pivotal trial, and neither may be marketed before regulatory approval.
The company funds its work through stock offerings and borrowing rather than customer payments. It needs additional capital to advance development. Any future drug-sales revenue would depend on successful trials, regulatory approval, physician prescribing and coverage and reimbursement from insurers and other payors.
ALX Oncology relies on outside organizations to run clinical trials and on contract manufacturers to supply its drugs; it has no manufacturing facilities of its own. Third-party European patents could also limit development of evorpacept for certain cancer uses in some EU territories unless the company obtains a license or the patent barriers are otherwise removed.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Pfizer’s cancer programs inherited from Trillium overlap with ALX Oncology’s evorpacept, while Pfizer also holds an exclusive license to related U.S. SIRPα patent rights. The drugmaker therefore matters both as a rival and through those patent rights, although ALX believes it does not infringe the issued U.S. patent.
Bristol Myers Squibb competes with both sides of ALX Oncology’s pipeline: CD47-pathway treatments overlap with evorpacept, and EGFR-targeted antibody-drug conjugates (ADCs) compete with its ADC program. The company already sells medicines for serious diseases; its development updates in those two areas are the news most relevant to ALX, which has no approved products or drug-sales revenue.
BioNTech’s EGFR-targeted antibody-drug conjugates (ADCs) compete with ALX Oncology’s emerging ADC pipeline. Although BioNTech’s commercial product is the Comirnaty COVID-19 vaccine, its EGFR-ADC development news is what matters for assessing competition facing ALX’s preclinical ALX2004 program.
AstraZeneca’s EGFR-targeted antibody-drug conjugates (ADCs) compete with ALX Oncology’s own EGFR-ADC development approach. AstraZeneca already earns revenue from selling cancer medicines, but its EGFR-ADC research progress is the relevant comparison for ALX’s still-preclinical ALX2004 program.
ALX Oncology depends on Eli Lilly to supply ramucirumab for certain evorpacept combination trials; Lilly manufactures and sells medicines. Watch whether that supply agreement continues through trial completion: if it ends early, ALX may need another source of ramucirumab.
ALX Oncology uses patent rights assigned by OmniAb’s Crystal Bioscience subsidiary and may owe payments as products reach specified clinical and regulatory milestones. OmniAb earns money by providing drug-discovery technology to partners; ALX’s agreement provides for up to $11.1 million in aggregate milestone payments, with each milestone payable only once across all products.
Fed Interest Rate Decision
The Fed’s decision tracks the policy interest rate that helps set borrowing costs; it can change what ALX Oncology pays each month on its $10.0 million of floating-rate loans.
Expected4.0%Last release4.0%
If it comes in above expectations
If the policy rate is above the estimate, higher rates can raise the loans’ interest costs and monthly cash outflow, although the 8.58% minimum rate may limit the increase.
If it comes in below expectations
If the policy rate is below the estimate, lower rates can reduce interest costs and monthly cash outflow if the loans’ rate falls; the 8.58% minimum may limit the savings.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb's report is worth watching for updates on its CD47-pathway work, which competes with ALX Oncology's evorpacept.
Watch for clinical progress or setbacks Bristol Myers Squibb reports in its CD47-pathway work. Progress would keep a competing approach to evorpacept in play; delays or setbacks could ease that pressure, but would not show that evorpacept works. The takeaway is whether this rival approach is still advancing.
Eli Lilly & Co. earningsLLY
Eli Lilly's report is worth watching because ALX Oncology relies on Lilly to supply ramucirumab for certain evorpacept trials, and a supply change could affect those studies.
Watch for any disclosure from Eli Lilly about ramucirumab supply or the related arrangement. If supply continues, ALX Oncology retains the stated source for those trials; if the arrangement ends early or supply is disrupted, ALX Oncology may need another source, adding work or delay risk. The takeaway is whether those trials still have a dependable supply path.
AstraZeneca PLC earningsAZN
AstraZeneca's report matters for updates on its EGFR-targeted antibody-drug conjugates, which compete with ALX Oncology's still-preclinical ALX2004 program.
Watch for clinical progress or setbacks AstraZeneca reports in its EGFR-targeted antibody-drug conjugate work. Progress would make the competing approach more established as ALX2004 remains preclinical; setbacks or delays could ease that pressure, but would not show that ALX2004 works. The takeaway is whether this competing drug approach is advancing.
ALX Oncology Holdings Inc. earningsThis company
ALX Oncology's report will show whether its research spending and cash use can support continued drug development without shortening the funding period management expects.
Read research and development costs alongside cash used in operations and the cash-and-investment balance; net loss is not the same as cash use. Slower cash use while development continues would support management's expectation that funding lasts through the first half of 2028. Faster cash use or a quicker fall in the balance would mean financing may be needed sooner. The question is whether available funds can support the development plan.
